

FORM PTO 1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0273-0006APPLICATION NO.  
10/026,914APPLICANT(S)  
Linhart, BirgitFILING DATE  
December 27, 2001GROUP  
1646 1645

JUN 20 2002

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AB2					
	AC2					
	AD2					
	AE2					
	AF2					
	AG2					
	AH2					
	AI2					
	AJ2					
	AK2					

RECEIVED

JUN 24 2002

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL2					<input type="checkbox"/> Yes <input type="checkbox"/> No
	AM2					<input type="checkbox"/> Yes <input type="checkbox"/> No
	AN2					<input type="checkbox"/> Yes <input type="checkbox"/> No
	AO2					<input type="checkbox"/> Yes <input type="checkbox"/> No
	AP2					<input type="checkbox"/> Yes <input type="checkbox"/> No

RECEIVED

NOV 05 2002

TECH CENTER 1600/2900

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	2	Mellerup, M.T., et al., "Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment," <i>Clinical and Experimental Allergy</i> , 30: 1423-1429 (2000).
AS	2	Noon, L., et al., "Prophylactic Inoculation Against Hay Fever, <i>The Lancet</i> , 1572-1573 (June 10, 1911).
AT	2	Niederberger, V., et al., "IgE antibodies to recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5, and Bet v 2) account for a high percentage of grass pollen-specific IgE," <i>The Journal of Allergy and Clinical Immunology</i> , 101: 258-64 (February 1998).

EXAMINER

DATE CONSIDERED

9/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.